First Light Diagnostics Receives FDA Clearance for its Rapid B. anthracis Toxin Test on the MultiPath® Analyzer
Rapid, sensitive test for the early diagnosis of inhalation anthrax Chelmsford, MA (December 5, 2023) – First Light Diagnostics announced that the US Food and Drug Administration (FDA) has cleared its SensiTox® B. anthracis Toxin Test to be marketed in the U.S. B. anthracis, the agent that causes anthrax, is a top biodefense concern due…
First Light Diagnostics Receives FDA Clearance for its Rapid Clostridiodes difficile Test on the MultiPath® Analyzer
First FDA cleared product based on the Company’s proprietary MultiPath technology Chelmsford, MA (Jul 20, 2021) – First Light Diagnostics is developing and commercializing breakthrough automated diagnostic products for rapidly detecting infections and determining optimal treatment. The company announced today that the US Food and Drug Administration (FDA) has cleared its SensiTox™ C. difficile Toxin…
First Light Diagnostics Appoints Joanne Spadoro as Chief Executive Officer
Chelmsford, MA (May 5, 2021) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening antibiotic resistant infections, has named Joanne Spadoro, PhD as President and Chief Executive Officer (CEO). As the CEO of First Light Diagnostics, Dr. Spadoro will be responsible for leading the company through the…
First Light Diagnostics Receives Additional Funding from the Biomedical Advanced Research and Development Authority (BARDA)
Funding Supports Continued Development of the SensiTox™ B. anthracis Toxin Test Chelmsford, MA, October 27, 2020 – First Light Diagnostics, Inc., a developer of breakthrough automated products for the rapid diagnosis and treatment of life-threatening infections, today announced the authorization of a $4 million award from the Biomedical Advanced Research and Development Authority (BARDA), part…
First Light Diagnostics Names New Chief Financial Officer
Life Sciences Veteran Andrew Wilsack Joins Team Chelmsford, MA (May 28, 2020) – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, has appointed Andrew Wilsack as the company’s new CFO. “Andrew’s broad experience across disciplines will be an asset for us,” said David Macdonald,…
First Light Diagnostics Posters and Abstracts Accepted, Part of ECCMID 2020 Abstract Book
Chelmsford, MA (May 21, 2020) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the acceptance of two posters as part of the 30th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). With global resources focused on combatting the current…
First Light Diagnostics Receives $1.1 Million ‘Paycheck Protection Program’ Loan Under the CARES Act
CHELMSFORD, Mass., May 19, 2020 – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, has acquired a “Paycheck Protection Program” (PPP) loan with the US Small Business Administration (SBA) as part of the US Coronavirus Aid, Relief and Economic Security (CARES) Act. The loan…
First Light Diagnostics Appoints New Chief Operating Officer
Seasoned Industry Veteran to Take Company Through Next Phase of Operations Chelmsford, MA (May 6, 2020) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, has named Dr. Joanne Spadoro as Chief Operating Officer (COO). Dr. Spadoro is a recognized leader in the in…
First Light Diagnostics Receives Additional Funding from the Biomedical Advanced Research and Development Authority (BARDA)
For development of the breakthrough MultiPath™ platform and culture-free, anti-microbial susceptibility tests Chelmsford, MA, December 18, 2019 – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, diagnosis and treatment of life-threatening, antibiotic-resistant infections, today announced the authorization of $4.3 million in additional funding from BARDA in support of First Light’s development…
First Light Diagnostics to Present at New England Venture Summit
CHELMSFORD, Mass., December 3, 2019 – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced David Macdonald, President and CEO of First Light Diagnostics, will be among the presenters at the 2019 New England Venture Summit. The New England Venture Summit is an event that allows…